Bionano Genomics, Inc.
corporate_fare Company Profile
Bionano Genomics, Inc. (NASDAQ:BNGO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 22 items for BNGO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for BNGO spans 10-Q, 8-K, S-3/A, S-3.
Recent high-impact activity:
- Bionano 10-Q: Q3 Revenue $8.3M, Going Concern Warning Reiterated, Cash $4.4M
- Bionano Q3 Revenue Up 12% to $8.3M; FY26 Guidance Reiterated at $31-33M
- Bionano Amends $400M Shelf; Adds $3.9M Sold Under Prior Shelf and $148.1M Carry-Forward
- Bionano Projects 56% Revenue Growth in FY27, EBITDA Break-Even by Q4 FY27
- Bionano Q2 revenue climbs 21%, but going concern warning persists as cash dwindles to $3.7M
Financial Snapshot
Short Interest & Short Volume
7.39 days to coverFINRA reported short interest of 1,387,664 shares in BNGO as of the October 30, 2026 settlement, a 2.0% increase from the prior period — about 7.4 days to cover at its recent average daily volume. On November 20, 2026, 22.9% of BNGO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BNGO, detected from its recent SEC filings · based on capital-structure filings through 2026-11-05.
Shelf Prospectus Filed Before Expiry · 1.33M Warrant Shares Registered
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →